More To Regeneron Pipeline Than Initially Meets Wall Street’s Eye
Executive Summary
Behind blockbuster seller Eylea and blockbuster hopeful PCSK9 inhibitor Praluent, Regeneron boasts a pipeline of 15 clinical candidates derived from its VelocImmune technology platform. Leading the next wave are sarilumab for rheumatoid arthritis and dupilumab for allergic indications, both partnered with Sanofi.